Osaka, Japan – Nitta Gelatin is pleased to announce the completion of its new R&D and manufacturing facility “Mirai-can,” December 14th, 2022. With the establishment of this state-of-the-art innovation hub, Nitta responds to the growing demand for biomedical products including low endotoxin collagen and gelatin for advanced medicine and biomedical research. In addition to ingredient production, this site will serve to expand Nitta Gelatin into the field of contract manufacturing for medical devices.
Following the Shinto ritual at the Mirai-can building, company president Koichi Ogata shared his thoughts on the future of the industry. “In recent years, it is expected that the use of collagen materials in biomedical fields such as regenerative medicine will expand both in Japan and overseas. In anticipation of strengthening and expanding our business in the medical field, Mirai-can has a production line and research and development functions for the latest medical collagen materials. We have also established a researcher office that incorporates ideas that promote creative activities and well-being work styles by researchers from different fields. From now on, Mirai-can will develop new products and cultivate new markets that will lead to the expansion of the business of the entire Mirai-can group.”
The new environmentally-friendly facility will be powered by renewable energy sources and feature a production plant, lab space, offices, and an event area opened to the community. For more information, check out the full press release here.